The House passed the BIOSECURE Act to prevent drug companies from doing business with specific Chinese biotechs. The bill prohibits the U.S. government from contracting with these companies and names five Chinese companies that would be affected. The next step is for the Senate to consider the bill during the lame duck session. The bill may be attached to a larger legislative package for approval. The true test will be in the Senate, where individual lawmakers have more power than in the House. The passage of the bill in the House makes it easier for BIOSECURE to be included in a legislative package.
Source link
House passes bill that targets China biotechs
